NCT02727283 - A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2015

Primary Completion Date

March 18, 2016

Study Completion Date

March 18, 2016

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

GSK3179106

GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg

DRUG

Placebo

Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths

Trial Locations (1)

5000

GSK Investigational Site, Adelaide